The diagnostics company Gradientech AB (publ) (“Gradientech” or the “Company”) today announces the outcome of the new issue of shares with preferential rights for existing shareholders (the “Rights Issue”) resolved by the Board of Directors on February 26, 2026. The final count in the Rights Issue shows that 5,619,127 shares, corresponding to approximately 87 percent of the Rights Issue, were subscribed for with and without the support of subscription rights. Through the Rights Issue, Gradientech will receive approximately SEK 49.2 million before deductions for issue costs, of which SEK 14 million will be used to offset loans.
Styrelsen i Gradientech AB (publ) (“Gradientech” eller “Bolaget”) beslutade den 26 februari 2026 att genomföra en nyemission av aktier med företrädesrätt för befintliga aktieägare om cirka 57 MSEK (“Företrädesemissionen”). Ett prospekt avseende Företrädesemissionen är godkännt av Finansinspektionen och finns tillgängligt på Bolagets hemsida gradientech.se (https://gradientech.se/investerare-sv/).
The Board of Directors of Gradientech AB (publ) (“Gradientech” or “the Company”) decided on 26 February 2026 to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 57 million (the “Rights Issue”). A prospectus regarding the Rights Issue is approved by the Swedish Financial Supervisory Authority and is available on the Company’s website gradientech.se (https://gradientech.se/investors/).
Styrelsen i Gradientech AB (publ) (“Gradientech” eller “Bolaget”) beslutade den 26 februari 2026 att genomföra en nyemission av aktier med företrädesrätt för befintliga aktieägare om cirka 57 MSEK (“Företrädesemissionen”). Ett prospekt avseende Företrädesemissionen kommer efter godkännande av Finansinspektionen att finnas tillgängligt på Bolagets hemsida gradientech.se (https://gradientech.se/investerare-sv/).
The Board of Directors of Gradientech AB (publ) (“Gradientech” or “the Company”) decided on 26 February 2026 to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 57 million (the “Rights Issue”). A prospectus regarding the Rights Issue will after approval by the Swedish Financial Supervisory Authority be available on the Company’s website gradientech.se (https://gradientech.se/investors/).
Increased commercial traction and regulatory progress strengthen the foundation for continued expansion
Ökad kommersiell genomslagskraft och regulatoriska framsteg stärker grunden för fortsatt expansion
The diagnostics company Gradientech today announces that it has received feedback from the U.S. Food and Drug Administration (FDA) regarding the company’s submitted 510(k) premarket notification for its QuickMIC[®] system for ultra-rapid antimicrobial susceptibility testing (AST) of bacterial isolates.
Diagnostikföretaget Gradientech meddelar idag att bolaget har mottagit återkoppling från den amerikanska läkemedelsmyndigheten FDA (U.S. Food and Drug Administration) avseende den 510(k)-ansökan som lämnats in för QuickMIC[®]-systemet för ultrasnabb antibiotikaresistensbestämning (AST) av bakterieisolat.
The diagnostics company Gradientech, specialised in ultra-rapid antibiotic susceptibility testing (AST), today announces a long-term agreement with ELBLAB GmbH in Germany for the use of its QuickMIC® system. The agreement strengthens Gradientech’s presence in one of its key European markets and demonstrates its commitment to providing advanced diagnostic solutions to healthcare providers.